Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom

Table 5

Base-case results for direct comparison of cost-effectiveness of pazopanib versus placebo.

	Pazopanib	Placebo	Pazopanib versus placebo
Effectiveness (discounted)
LYs	1.375	1.262	0.113
PFLYs	0.503	0.211	0.292
PPLYs	0.872	1.051	−0.179
QALYs	0.719	0.591	0.128
Costs (discounted), £
Study medication	10,733	0	10,733
Administration	81	0	81
Adverse events	251	54	197
Other costs PFS	557	234	323
Other costs PPS	10,463	13,822	−3,359
Total	22,086	14,110	7,976
Cost per QALY gained			62,162

LYs: life-years; PFLYs: progression-free life-years; PFS: progression-free survival; PPLYs: postprogression life-years; PPS: postprogression survival; QALYs: quality-adjusted life-years.